A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 307 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Dame Deborah James: why do deeply personal stories resonate with us... May 24, 2022 The American Rescue Act: What You Need to Know March 16, 2021 Will This Cancer Metastasize? Check Its “Stickiness” May 6, 2025 ESMO Highlights Key Issues for Patients with Cancer and Their Carers... May 27, 2025 Load more HOT NEWS Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer Plans for NCI’s Fiscal Year 2019 Budget Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage...
